Skip to Main Content

Paper Details

Targeting aberrant glutathione metabolism to eradicate human acute myelogenous leukemia cells.
J Biol Chem
144
2013
AML, AML cells, CD34(, CD34(+, CD34(+), CD34(+) AML cells, GCLC, GPX1, PTL, acute myelogenous leukemia, acute myelogenous leukemia cells, glutathione, human, human AML cells, leukemia, leukemia stem cells, leukemic, leukemic cells, normal CD34(+) cells, oxidized glutathione, parthenolide, piperlongumine, primary, primary human AML cells, primary human acute myelogenous leukemia (AML) cells, primitive (CD34(+)), primitive leukemia, primitive leukemia cells, reduced glutathione
Author NameAffiliation
Shanshan PeiUniversity of Rochester School of Medicine, University of Colorado Denver
Mohammad MinhajuddinUniversity of Colorado Denver
Haobin YeUniversity of Colorado Denver, University of Rochester School of Medicine
Cyril H BenesMassachusetts General Hospital Cancer Center and Harvard Medical School
Michael W BeckerUniversity of Rochester School of Medicine
Veronica Clavijo JordanUniversity of Rochester School of Medicine, University of Colorado Denver
Veronica Clavijo JordanUniversity of Rochester School of Medicine, University of Colorado Denver
  • 1 - 7

Datasets

Release 1.2